Skip to main content

Tusdec-HC Side Effects

Generic name: hydrocodone / phenylephrine

Note: This document contains side effect information about hydrocodone / phenylephrine. Some of the dosage forms listed on this page may not apply to the brand name Tusdec-HC.

Applies to hydrocodone/phenylephrine: oral liquid, oral syrup

General

The most common adverse events were occasional drowsiness, dry mouth, blurred vision, dizziness, mild mental stimulation, and gastric irritation.[Ref]

Nervous system

Rare (less than 0.1%): Occasional drowsiness, dizziness, mild mental stimulation

Postmarketing reports: Convulsions[Ref]

Respiratory

Postmarketing reports: Breathing difficulties[Ref]

Genitourinary

Postmarketing reports: Urinary retention, androgen deficiency[Ref]

Androgen deficiency:

-Chronic opioid use may affect the hypothalamic-pituitary-gonadal axis leading to androgen deficiency.

-Symptoms may include low libido, impotence, erectile dysfunction, amenorrhea, and infertility.

-Opioids role in androgen deficiency have not been evaluated where other factors (medical, physical, lifestyle, psychological) have been adequately controlled.

-Perform laboratory evaluation for symptoms of androgen deficiency.[Ref]

Psychiatric

Rare (less than 0.1%): Mild mental stimulation

Postmarketing reports: Hallucinations[Ref]

Cardiovascular

Postmarketing reports: Rapid heart rate, reflex bradycardia[Ref]

Ocular

Rare (less than 0.1%): Blurred vision[Ref]

Hypersensitivity

Postmarketing reports: Allergic reaction[Ref]

Gastrointestinal

Rare (less than 0.1%): Dry mouth, gastric irritation[Ref]

More about Tusdec-HC (hydrocodone / phenylephrine)

Related treatment guides

References

1. Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):

2. "PDR Generics. 4th ed." Montvale, NJ: Medical Economics (1998):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.